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Abstract
Background: To report a case of metastatic hepatocholangiocarcinoma to the vitreous and retina.
Case presentation: A 70-year-old male, who was recently diagnosed with hepatocholangiocarcinoma, was
complaining of floaters in his right eye over the past 5 months and was referred to the Liverpool Ocular Oncology
Centre. On presentation, his visual acuity in the right eye was 6/24. Fundus exam revealed a whitish, unilateral, full-
thickness retinal lesion at the inferotemporal arcade of his right eye, with vitreous infiltration and subretinal fluid.
The patient underwent 25G pars plana vitrectomy with biopsy, resection of the lesion and intravitreal bevacizumab
injection. Histopathology testing of the surgical specimens confirmed the diagnosis of metastatic carcinoma to the
eye. Two months postoperatively his visual acuity had improved to 6/7.5 and there was no sign of active disease in
his right eye, while 9 months postoperatively his visual acuity decreased to 6/9.5 due to developing nuclear
sclerotic cataract in his right eye.
Conclusion: The current report presents the first case of a hepatocholangiocarcinoma metastasis to the vitreous and retina.
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Background
Hepatocellularcarcinoma (HCC) and cholangiocellularcar-
cinoma (CCC) within the same liver, is designated as hepa-
tocholangiocarcinoma (HCC/CCC) [1]. Uveal metastasis is
the most common intraocular malignancy, [2] while retinal
metastasis is rare [3]. Retinal metastasis from HCC/CCC
was not previously reported in the literature. We present
the first case of metastatic spread of HCC/CCC to the
retina and vitreous.
Case presentation
A 70-year-old male was referred to Liverpool Ocular
Oncology Centre (LOOC), complaining of floaters in his
right eye (RE) over the past 5 months. One month before
presentation to LOOC, the patient presented to Oncology
Department with abdominal pain, lack of appetite and
weight loss. The patient was diagnosed by Medical
Oncologists with HCC/CCC with multiple liver metasta-
ses. The diagnosis of HCC/CCC was made via endoscopic
ultrasound (EUS) and fine-needle aspiration (FNA) with
19G needle of the primary tumour which sent for hist-
ology and confirmed the diagnosis. Computed tomog-
raphy (CT) scan confirmed the presence of liver
metastases. The staging of the tumour was T3N1M1 and/
or stage IV B (liver metastases).
On presentation to LOOC, best corrected visual acuity
(BCVA) was 6/24 in RE and 6/4.8 in left eye. Fundus
examination of his RE showed a single whitish elevated
lesion 3–4 DD in size at the infero-temporal arcade asso-
ciated with vitreous infiltration and intra- and sub-retinal
fluid. (Fig. 1a-c) The patient underwent a 25G pars plana
vitrectomy with excisional biopsy of the affected tissue, re-
section of the lesion, peeling of the epiretinal membrane,
air tamponade and intravitreal bevacizumab (anti-VEGF)
injection. Four surgical specimens were sent for histopath-
ology test which confirmed the diagnosis of metastatic
carcinoma to the vitreous and retina (Fig. 2). The patient
was started on cycles of palliative chemotherapy intraven-
ously with gemcitabine 1000 mg/m2 on days 1 and 8 along
with cisplatin 70 mg/m2 on day 1, after intraocular
metastatic disease was diagnosed.
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One month postoperatively, his BCVA has improved to 6/
9.5 in his RE and fundoscopy revealed peripheral retinal
haemorrhage and subretinal haemorrhage near the resolving
metastatic lesion. Two months postoperatively the BCVA
had improved to 6/7.5 and there was no sign of active disease
in his RE (Fig. 1d-f). Four months postoperatively fundos-
copy showed telengiectatic vessels on thickened retina with
no vitreous infiltration. Six months postoperatively there
were pigmentary changes at the site of metastatic lesion, the
vitreous was clear and there were no new lesions. Nine
months postoperatively his BCVA decreased to 6/9.5 due to
developing nuclear sclerotic cataract in his RE, while the vit-
reous was clear, with no reactivation and no new ophthalmic
lesions. Metastatic intraocular lesion had stable regression
after treatment with vitrectomy, excisional biopsy and sys-
temic chemotherapy for the duration of ocular follow-up.
The patient underwent in total 8 cycles of palliative
chemotherapy with gemcitabine along with cisplatin ap-
proximately every 4 weeks but unfortunately succumbed to
widespread metastatic disease 5 weeks after completion of
last chemo cycle and one year after the initial diagnosis of
the primary disease.
Discussion
HCC/CCC has emerged as a distinct subtype; it represents
less than 1% of primary liver cancers [4]. There are no clearly
defined diagnostic criteria, and no guidelines regarding ther-
apy [5]. Known risk factors include cholelithiasis, cirrhosis
and viral hepatitis [4, 5]. HCC/CCC metastasizes through the
venous or lymphatic system or along the biliary lumen with a
predilection for the liver [4]. Its distant metastases are rare;
however, bony metastases were noted in one patient [5].
There is only one case in the literature of a solitary lacrimal
gland tumor from metastatic HCC [6].
Metastatic lesions are the most common intraocular ma-
lignancies. The majority of intraocular metastases affect the
choroid, while the ciliary body, the iris, the retina and the
vitreous are less frequently affected. The current case
illustrates the first case of a rare site of metastasis to the vit-
reous and retina for HCC/CCC. Breast and lung cancer
most commonly metastasises to the uvea [2, 3]. Patients
with ocular metastasis most often present with blurring vi-
sion, metamorphopsia, floaters, photopsia, and a visual field
defect [2]. Our patient was complaining of floaters in his
RE over the past 5 months. Retinal metastases are usually
unilateral, appear white, yellow, or brown; are located in
the inner retina or full-thickness retina; and have vitreous
infiltrates, vitreous hemorrhage, retinal hemorrhage, subret-
inal fluid, intraretinal exudation [3] and are initially often
misdiagnosed as retinitis, hemangioma, choroidal neovas-
cular membrane, or nerve fiber layer infarction [3]. In the
present case it was a unilateral white, full-thickness retinal
lesion with vitreous infiltration and subretinal fluid, which
resembled the clinical picture of a localized retinitis.
As the patient presented with a recently diagnosed
systemic malignancy and some primary tumours tend to
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Fig. 1 a Colour wide angle fundus picture of the right eye of the patient at presentation showed a single whitish elevated lesion at the infero-temporal
arcade associated with vitreous infiltration and retinal fluid, b Spectral Domain OCT of the right macula of the patient at presentation showing intraretinal
and subretinal fluid, c Spectral Domain OCT through the lesion at presentation showing full thickness retinal lesion with vitreous involvement d Colour
wide angle fundus picture of the right eye of the patient two months postoperatively showed clear vitreous, no new retinal lesion and no signs of any
active eye disease, e Spectral Domain OCT of the right macula of the patient two months postoperatively showing complete regression of the retinal fluid,
f Spectral Domain OCT through the lesion two months postoperatively showing total anatomical restoration of the retinal layers
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metastasize to the retina and vitreous, the suspected
diagnosis was that of retinal and vitreous metastatic lesion.
The differential diagnosis included fungal endophthalmitis
an infectious retinitis of unknown origin. The biopsy was
performed to establish the suspected diagnosis of an intra-
ocular metastasis against the background of the unusual
location of the lesion [2, 3] as the treatment for these en-
tities varies significantly and severe and permanent visual
loss was to be expected in case of progressive, untreated
disease. Our patient was diagnosed with a metastatic
HCC/CCC to the vitreous and retina which was confirmed
by biopsy. Treatment of ocular metastasis includes radio-
therapy, resection with/out intravitreal anti-VEGF injec-
tion, enucleation, observation along with/or systemic
chemotherapy or biologic therapy [2, 3].
Conclusion
In conclusion, the current report presents the first case of
unusual HCC/CCC metastasis to the vitreous and retina. A
retinal and vitreous biopsy was required to establish the
diagnosis, while the therapeutic options for this case
included local treatment for the intraocular metastasis and
systemic chemotherapy for the primary lesion and its
metastatic disease.
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Fig. 2 Histopathology examination of retinal and vitreous specimens
established the diagnosis of metastatic carcinoma; a Cytology
preparation stained with May-Grunwald Giemsa stain (MGG) showing
groups of atypical epithelioid cells, some of which with cytoplasmic
vacuolation; b Immunocytochemistry demonstrating cytoplasmic and
membranous expression of tumour cells by pan-epithelial marker AE1/
AE3 and carcinoembryonic antigen (CEA)
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